Wilms tumor and the WT1 gene

Experimental Cell Research

Volumn 264, Issue 1, 2001, Pages 74-99

  Lee, Sean Bong ^a   Haber, Daniel A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MESSENGER RNA; PROTEIN WT1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CHROMOSOME 11P; CHROMOSOME TRANSLOCATION; DNA BINDING; GENE FUSION; GENE INACTIVATION; GENE INSERTION; GENE MUTATION; GENETIC PREDISPOSITION; HEMATOPOIESIS; HUMAN; KIDNEY DEVELOPMENT; MESOTHELIUM CELL; MOLECULAR CLONING; MOUSE STRAIN; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; RNA PROCESSING; SEX DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

EID: 0035835816     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2000.5131     Document Type: Article

References (251)

1. Tumors of the kidney, renal pelvis, and ureter
2. Loss of WT1 function leads to ectopic myogenesis in Wilms' tumour
3. Wilms' tumor: Status report, 1990
4. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
5. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors
6. Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour
7. Development of homozygosity for chromosome 11p markers in Wilms' tumour
8. Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumours
9. Loss of a Harvey ras allele in sporadic Wilms' tumour
10. Molecular definition of the 11p15.5 region involved in Beckwith-Wiedemann syndrome and probably in predisposition to adrenocortical carcinoma
11. Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells
12. Chromosome analysis of 31 Wilms' tumors
13. A third Wilms' tumor locus on chromosome 16q
14. Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour
15. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome
16. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters
17. Mutation and cancer: A model for Wilms' tumor of the kidney
18. Multifocal nephroblastic neoplasia
19. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor
20. Constitutional WT1 mutations in Wilms' tumor patients
21. Are bilateral tumours hereditary?
22. Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21
23. Association of Wilms' tumor with aniridia, hemihypertrophy and other congenital malformations
24. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
25. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumpping
26. Congenital anomalies in children with Wilms' tumor, a new survey
27. Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion
28. Aniridia-Wilms' tumor association: Evidence for specific deletion of 11p13
29. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour
30. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome
31. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour
32. Evidence for WT1 as a Wilms tumor (WT) gene: Intragenic germinal deletion in bilateral WT
33. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region
34. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5
35. Genetic linkage of Beckwith-Wiedemann syndrome to 11p15
36. Abnormality of chromosome 11 in patients with features of Beckwith-Wiedemann syndrome
37. Complexe malformatif familial avec hernie ombilicale et macroglossie - Un syndrome nouveau?
38. Macroglossia, omphalocele, adrenal cytomegaly, gigantism and hyperplastic visceromegaly
39. Uniparental paternal disomy in a genetic cancer-predisposing syndrome
40. Chromosome 11 uniparental isodisomy predisposing to embryonal neoplasms
41. Parental genomic imprinting of the human IGF2 gene
42. IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome
43. Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms' tumour and gigantism
44. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome
45. Expression of insulin-like growth factor-II transcripts in Wilms' tumour
46. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues
47. Relaxation of imprinted genes in human cancer
48. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour
49. Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse
50. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15
51. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome
52. Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes
53. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome
54. Oppositely imprinted genes p57(Kip2) and igf2 interact in a mouse model for Beckwith-Wiedemann syndrome
55. Parental imprinting of the mouse H19 gene
56. Tumour-suppressor activity of H19 RNA
57. Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumours
58. Alternative splicing and genomic structure of the Wilms tumor gene WT1
59. Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient
60. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome
61. Germline intronic and exonic mutations in the Wilms' tumour gene (WT1) affecting urogenital development
62. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome
63. A novel mutation of the WT1 gene (a tumor suppressor gene for Wilms' tumor) in a patient with Denys-Drash syndrome
64. A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome
65. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion
66. A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells
67. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins
68. Antagonism of WT1 activity by protein self-association
69. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein
70. Donor splice-site mutations in WT1 are responsible for Frasier syndrome
71. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms
72. Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms, are also responsible for Frasier syndrome
73. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor
74. Structural rearrangements of the WT1 gene in Wilms' tumour cells
75. Zinc finger point mutations within the WT1 gene in Wilms tumor patients
76. Homozygous somatic Wt1 point mutations in sporadic unilateral Wilms tumor
77. Fine structure analysis of the WT1 gene in sporadic Wilms tumors
78. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant
79. New developments in the pathology of Wilms tumor
80. The candidate Wilms' tumour gene is involved in genitourinary development
81. Expression of the Wilms' tumor gene WT1 in the murine urogenital system
82. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma
83. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo
84. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development
85. Inductive tissue interactions, cell signaling, and the control of kidney organogenesis
86. Cross-talk in kidney development
87. A mouse model of the aniridia-Wilms tumor deletion syndrome
88. WT-1 is required for early kidney development
89. Initial differentiation of the metanephric mesenchyme is independent of WT1 and the ureteric bud
90. The Wilms tumor suppressor gene wt1 is required for development of the spleen
91. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis
92. YAC transgenic analysis reveals Wilms' tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb
93. Sp1 is a critical regulator of the Wilms' tumor-1 gene
94. Repression of Pax-2 by WT1 during normal kidney development
95. The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1)
96. Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2
97. Effects of PAX2 expression in a human fetal kidney (HEK293) cell line
98. PAX8-mediated activation of the wt1 tumor suppressor gene
99. PAX 8 regulates human WT1 transcription through a novel DNA binding site
100. The Wilms' tumor suppressor gene WT1 is negatively autoregulated
101. Autoregulation of the human WT1 gene promoter
102. Differential function of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation
103. Pax2 a new murine paired-Box-Containing gene its expression in the developing excretory system
104. Zebrafish no isthmus reveals a role for pax2.1 in tubule differentiation and patterning events in the pronephric primordia
105. Expression of the Wilms' tumor gene (WT1) in human leukemias
106. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias
107. Transactivation of an intronic hematopoietic-specific enhancer of the human Wilms' tumor 1 gene by GATA-1 and c-Myb
108. GATA-1 transactivates the WT1 hematopoietic specific enhancer
109. Expression of the Wilms' tumor suppressor gene, WT1, is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells
110. Mesenchymal to epithelial conversion in rat metanephros is induced by LIF
111. Induction of kidney epithelial morphogenesis by cells expressing Wnt-1
112. Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney
113. Rat renal mesenchymal tumor as an experimental model for human congenital mesoblastic nephroma: I. Induction
114. Renal tumors induced transplacentally in the rat by n-ethylnitrosourea
115. Rat renal mesenchymal tumor as an experimental model for human congenital mesoblastic nephroma. II. Comparative pathology
116. A rodent model for Wilms tumors: Embryonal kidney neoplasms induced by N-nitroso-N′-methylurea
117. Wilms' tumor suppressor gene is involved in the development of disparate kidney forms: Evidence from expression in the Xenopus pronephros
118. Precocious expression of the Wilms' tumor gene xWT1 inhibits embryonic kidney development in Xenopus laevis
119. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways
120. Transcriptional repression mediated by the WT1 Wilms tumor gene product
121. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence
122. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing
123. The evolution of WT1 sequence and expression pattern in the vertebrates
124. Complete sequencing of the Fugu WAGR region from WT1 to PAX6: Dramatic compaction and conservation of synteny with human chromosome 11p13
125. cDNA cloning and its pronephros-specific expression of the Wilms' tumor suppressor gene, WT1, from Xenopus laevis
126. RNA editing in the Wilms' tumor susceptibility gene, WT1
127. A non-AUG translational initiation event generates novel WT1 isoforms
128. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties
129. Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product
130. Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins
131. The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains
132. The WT1 Wilms' tumor suppressor gene: How much do we really know?
133. The transcriptional effect of WT1 is modulated by choice of expression vector
134. Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70
135. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1
136. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization
137. DNA recognition by splicing variants of the Wilms' tumor suppressor, WT1
138. A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1
139. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis
140. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product
141. The Wilms suppressor WT1 encodes a transcriptional activator of amphiregulin
142. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene
143. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript
144. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers
145. The WT1 Wilms tumor gene product: A developmentally regulated transcription factor in the kidney that functions as a tumor suppressor
146. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1
147. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene
148. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1
149. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product
150. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression
151. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus
152. Repression of the transforming growth factor-beta I gene by the Wilms' tumor suppressor WT1 gene product
153. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1
154. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1
155. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1
156. The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas
157. Wilms' tumor protein WT1 as an ovarian transcription factor: Decreases in expression during follicle development and repression of inhibin-alpha gene promoter
158. LLC-PK1 cell growth is repressed by WT1 inhibition of G-protein alpha i-2 protooncogene transcription
159. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene
160. Analysis of WT1 target gene expression in stably transfected cell lines
161. Physical and functional interaction between WT1 and p53 proteins
162. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells
163. Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control
164. G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes
165. The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation
166. Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression
167. E-cadherin is a WT1 target gene
168. Targeted disruption of Bcl-2 ab in mice: Occurrence of grey hair, polycystic kidney disease and lymphocytopenia
169. Fulminant metanephric apoptosis and abnormal kidney development in bcl-2-deficient mice
170. Bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys and hypopigmented hair
171. Epithelial-mesenchymal interactions regulate the stage-specific expression of a cell surface proteoglycans, syndecan, in the developing kidney
172. Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition
173. Induction of p21 by the Wilms' tumor suppressor gene WT1
174. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity
175. Structure and function of human amphiregulin: A member of the epidermal growth factor family
176. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development
177. Identification of connective tissue growth factor as a target of WT1 transcriptional regulation
178. The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor (VDR)
179. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues
180. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes
181. Presence of WT1, the Wilm's tumor suppressor gene product, in nuclear poly(A)(+) ribonucleoprotein
182. RNA binding by the Wilms tumor suppressor zinc finger proteins
183. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product
184. An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling
185. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis
186. Physical interaction between Wilms tumor 1 and p73 proteins modulates their functions
187. E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells
188. The human heat shock protein hsp70 interacts with HSF, the transcription factor that regulates heat shock gene expression
189. The DNA-binding activity of the human heat shock transcription factor is regulated in vivo by hsp70
190. Activation of heat shock factor 1 DNA binding precedes stress-induced serine phosphorylation: Evidence for a multistep pathway of regulation
191. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1
192. Ciao 1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1
193. Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9
194. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins
195. Identification of WTAP, a novel Wilms' tumour 1-associating protein
196. Regulation of WT1 by phosphorylation: Inhibition of DNA binding, alteration of transcriptional activity and cellular translocation
197. Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain
198. Expression of steroidogenic factor 1 and Wilms' tumour 1 during early human gonadal development and sex determination
199. Expression and subcellular localization of SF-1, SOX9, WT1, and AMH proteins during early human testicular development
200. A dosage sensitive locus at chromosome Xp21 is involved in male to female sex reversal
201. Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR to steroidogenic factor 1
202. Wilms' tumor suppressor gene (WT1) as a target gene of SRY function in a mouse ES cell line transfected with SRY
203. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Mullerian-inhibiting substance, and the androgen receptor
204. Wilms' tumor suppressor gene expression in rat and human mesothelioma
205. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma
206. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression
207. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): Desmoplastic small round-cell tumor and its variants
208. Case 2: Desmoplastic small cell tumor with divergent differentiation
209. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor
210. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor
211. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
212. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains
213. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma
214. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II
215. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP
216. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG
217. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1
218. Fusion of the EWS and CHOP genes in myxoid liposarcoma
219. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts
220. Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma
221. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1
222. The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma - Wilms' tumor 1 fusion protein
223. The DNA binding domains of the WT1 tumor suppressor gene product and chimeric EWS/WT1 oncoprotein are functionally distinct
224. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour
225. The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties
226. Mutations in the Wilms' tumor gene WT1 in leukemias
227. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies
228. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance
229. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis
230. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
231. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
232. Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia
233. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia
234. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis
235. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines
236. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells
237. Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program
238. Wilms' tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain
239. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice
240. The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells
241. Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells
242. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells
243. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro
244. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth
245. The tumor suppressor gene WT1 inhibits ras-mediated transformation
246. Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor
247. Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apoptotic cell death in response to retinoic acid
248. Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1)
249. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter
250. Regulation of nov by WT1: A potential role for nov in nephrogenesis
251. Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1